JP2019513828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513828A5 JP2019513828A5 JP2019503599A JP2019503599A JP2019513828A5 JP 2019513828 A5 JP2019513828 A5 JP 2019513828A5 JP 2019503599 A JP2019503599 A JP 2019503599A JP 2019503599 A JP2019503599 A JP 2019503599A JP 2019513828 A5 JP2019513828 A5 JP 2019513828A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- formula
- compound
- composition according
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 235000014113 dietary fatty acids Nutrition 0.000 claims 6
- 229930195729 fatty acid Natural products 0.000 claims 6
- 239000000194 fatty acid Substances 0.000 claims 6
- 150000004665 fatty acids Chemical class 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 239000000829 suppository Substances 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000002511 suppository base Substances 0.000 claims 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims 1
- 239000005639 Lauric acid Substances 0.000 claims 1
- 235000021360 Myristic acid Nutrition 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000004671 saturated fatty acids Chemical class 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662318946P | 2016-04-06 | 2016-04-06 | |
| US62/318,946 | 2016-04-06 | ||
| AUPCT/AU2016/050674 | 2016-07-28 | ||
| PCT/AU2016/050674 WO2017173474A1 (en) | 2016-04-06 | 2016-07-28 | Improvements in cancer treatment |
| US201762480692P | 2017-04-03 | 2017-04-03 | |
| US62/480,692 | 2017-04-03 | ||
| PCT/AU2017/050301 WO2017173498A1 (en) | 2016-04-06 | 2017-04-06 | Isoflavonoid composition with improved pharmacokinetics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513828A JP2019513828A (ja) | 2019-05-30 |
| JP2019513828A5 true JP2019513828A5 (enExample) | 2020-05-21 |
Family
ID=60000544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503599A Ceased JP2019513828A (ja) | 2016-04-06 | 2017-04-06 | 改善された薬物動態を有するイソフラボノイド組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11559510B2 (enExample) |
| EP (2) | EP3439644B1 (enExample) |
| JP (1) | JP2019513828A (enExample) |
| AU (1) | AU2017247008B2 (enExample) |
| CA (1) | CA3058503A1 (enExample) |
| WO (1) | WO2017173498A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3439642A4 (en) * | 2016-04-06 | 2019-11-13 | Noxopharm Limited | IMPROVEMENTS IN RADIOTHERAPY |
| CA3058500A1 (en) * | 2016-04-06 | 2017-10-12 | Noxopharm Limited | Targeted drug delivery |
| AU2017247008B2 (en) | 2016-04-06 | 2022-04-07 | Noxopharm Limited | Isoflavonoid composition with improved pharmacokinetics |
| WO2021007618A1 (en) * | 2019-07-17 | 2021-01-21 | Noxopharm Limited | Immuno-oncology therapy using isoflavone compounds |
| EP4125870A1 (en) | 2020-03-30 | 2023-02-08 | Noxopharm Limited | Methods for the treatment of inflammation associated with infection |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0676314B2 (ja) * | 1985-09-30 | 1994-09-28 | 花王株式会社 | 坐剤基剤及び坐剤 |
| AUPO203996A0 (en) | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| AUPQ008299A0 (en) | 1999-04-30 | 1999-05-27 | G.J. Consultants Pty Ltd | Isoflavone metabolites |
| AUPQ266199A0 (en) | 1999-09-06 | 1999-09-30 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
| US20090233999A1 (en) | 1999-09-06 | 2009-09-17 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
| AUPR363301A0 (en) | 2001-03-08 | 2001-04-05 | Novogen Research Pty Ltd | Dimeric isoflavones |
| US8178123B2 (en) | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| AUPR846401A0 (en) | 2001-10-25 | 2001-11-15 | Novogen Research Pty Ltd | 6-Hydroxy isoflavones, derivatives and medicaments involving same |
| EP1503751A4 (en) | 2002-04-09 | 2007-08-01 | Novogen Res Pty Ltd | THERAPEUTIC PROCESSES AND COMPOSITIONS WITH ISOFLAV-3-EN AND ISOFLAVAN STRUCTURES |
| CA2492754C (en) | 2002-07-24 | 2018-05-22 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
| AU2002951833A0 (en) | 2002-10-02 | 2002-10-24 | Novogen Research Pty Ltd | Compositions and therapeutic methods invloving platinum complexes |
| AU2002952453A0 (en) | 2002-11-01 | 2002-11-21 | Novogen Research Pty Ltd | Aminated isoflavonoid derivatives and uses thereof |
| AU2004273910A1 (en) | 2003-09-18 | 2005-03-31 | Combinatorx, Incorporated | Combinations of drugs for the treatment of neoplasms |
| JP2007525485A (ja) * | 2003-11-19 | 2007-09-06 | ノボゲン リサーチ ピーティーワイ リミテッド | 複合的な放射線治療及び化学治療の組成物及び方法 |
| US20050154452A1 (en) * | 2003-12-23 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
| US7434690B2 (en) | 2004-04-30 | 2008-10-14 | Cutispharma, Inc. | Container and method for the preparation, storage and dispensing of compounded suppositories |
| ATE532777T1 (de) | 2004-09-21 | 2011-11-15 | Marshall Edwards Inc | Substituierte chromanderivate, medikamente und anwendungen in der therapie |
| WO2006032086A1 (en) | 2004-09-21 | 2006-03-30 | Novogen Research Pty Ltd | Chroman derivatives, medicaments and use in therapy |
| DE102005009515A1 (de) | 2005-02-25 | 2006-09-07 | Exner, Heinrich, Dr. | Verfahren zur Herstellung einer Zubereitung einer DMSO-haltigen festen Silikonölemulsion zur Bindung von reaktiven Sauerstoffverbindungen im Körper von Menschen und Tieren |
| CN101203219B (zh) | 2005-03-24 | 2011-06-15 | 诺沃根研究控股有限公司 | 消炎用药程式 |
| EP1948103A2 (en) | 2005-09-15 | 2008-07-30 | UMD, Inc. | A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration |
| US20070196381A1 (en) | 2006-02-17 | 2007-08-23 | Natures Benefit, Inc. | Herbal compositions, methods of stimulating immunomodulation and enhancement of immunomodulating agents using the herbal compositions |
| WO2008052256A1 (en) * | 2006-10-30 | 2008-05-08 | Novogen Research Pty Ltd | Prevention and reversal of chemotherapy-induced peripheral neuropathy |
| EP2160385A4 (en) * | 2007-06-29 | 2010-10-27 | Novogen Res Pty Ltd | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS AND MEDICAMENTS THEREOF AND APPLICATIONS THEREOF |
| EP2334296A4 (en) | 2008-08-29 | 2012-04-25 | Novogen Res Pty Ltd | IMMUNOMODULATING ACTIVITIES |
| EP2365955B1 (en) | 2008-11-14 | 2014-12-31 | Heartlink Limited | Aryl di-substituted propenone compounds |
| KR20110004525A (ko) * | 2009-07-08 | 2011-01-14 | 동의대학교 산학협력단 | 제니스테인과 ｔｒａｉｌ을 포함하는 간암 치료용 조성물 |
| ES2365960B1 (es) | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| EP2766500A4 (en) | 2011-10-14 | 2015-10-14 | Univ Ohio State | METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER |
| KR20220123335A (ko) | 2013-03-13 | 2022-09-06 | 온코슈틱스 인코포레이티드 | 7-벤질-10-(2-메틸벤질)-2,6,7,8,9,10-헥사하이드로이미다조[1,2-a]피리도[4,3-d]피리미딘-5(3h)-온과의 조합 치료요법 |
| US20150126597A1 (en) | 2013-11-07 | 2015-05-07 | Humanetics Corporation | Genistein cancer treatment regimen maximizing cancer radiation therapy benefits |
| PL2953938T3 (pl) | 2014-02-07 | 2017-12-29 | Novogen Ltd. | Funkcjonalizowane związki benzopiranowe i ich zastosowanie |
| HRP20220738T1 (hr) | 2014-08-11 | 2022-08-19 | Acerta Pharma B.V. | Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1 |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| EP4512394A3 (en) * | 2015-06-03 | 2025-10-22 | Triastek, Inc. | Dosage forms and use thereof |
| US10561653B2 (en) | 2015-08-11 | 2020-02-18 | Novartis Ag | 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer |
| AU2016349632A1 (en) | 2015-11-07 | 2018-05-24 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| KR20190016017A (ko) | 2016-04-06 | 2019-02-15 | 녹소팜 리미티드 | 암 치료제의 개선 |
| AU2017247008B2 (en) | 2016-04-06 | 2022-04-07 | Noxopharm Limited | Isoflavonoid composition with improved pharmacokinetics |
| EP4035667A1 (en) * | 2016-04-22 | 2022-08-03 | Noxopharm Limited | Chemotherapy improvements with idronoxil |
| CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| AU2019285641A1 (en) | 2018-06-15 | 2021-04-08 | The Board Of Regents Of The University Of Texas System | Methods of treating and preventing melanoma with s-equol |
| AU2019285640A1 (en) | 2018-06-15 | 2021-01-21 | Board Of Regents Of The University Of Texas System | Methods of treating and preventing breast cancer with S-equol |
| WO2020051644A1 (en) | 2018-09-13 | 2020-03-19 | Norbio No. 2 Pty Ltd | Treatment of peripheral nervous tissue inflammation |
-
2017
- 2017-04-06 AU AU2017247008A patent/AU2017247008B2/en not_active Ceased
- 2017-04-06 JP JP2019503599A patent/JP2019513828A/ja not_active Ceased
- 2017-04-06 EP EP17778482.4A patent/EP3439644B1/en not_active Not-in-force
- 2017-04-06 CA CA3058503A patent/CA3058503A1/en not_active Abandoned
- 2017-04-06 US US16/091,716 patent/US11559510B2/en active Active
- 2017-04-06 WO PCT/AU2017/050301 patent/WO2017173498A1/en not_active Ceased
- 2017-04-06 EP EP21214664.1A patent/EP4005567A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020097577A5 (enExample) | ||
| JP2014525449A5 (enExample) | ||
| RU2013147744A (ru) | Дозированная лекарственная форма для перорального применения | |
| JP2019526596A5 (enExample) | ||
| JP2009530398A5 (enExample) | ||
| WO2004009121A1 (en) | Pharmaceutical compositions comprising hepatitis c viral protease inhibitors | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2018505169A5 (enExample) | ||
| AR067824A1 (es) | Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer. | |
| AR059481A1 (es) | Derivados de 1, 3-dihidro-imidazo[4, 5-c]piridin-2-ona como agonista del receptor tlr7, un metodo para su preparacion, intermediarios de sintesis de los mismos, una composicion farmaceutica que los comprende y su uso en la elaboracion de un medicamento para el tratamiento de infecciones viricas. | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| JP2004517843A5 (enExample) | ||
| AR045040A1 (es) | Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos | |
| JP2016516773A5 (enExample) | ||
| JP2015522033A5 (enExample) | ||
| RU2014119858A (ru) | Применение мелатонина для лечения и/или предотвращения мукозита | |
| JP2016531895A5 (enExample) | ||
| AR030039A1 (es) | Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento | |
| JP2017532316A5 (enExample) | ||
| RU2017110076A (ru) | Фармацевтическая композиция и способы | |
| AR120174A1 (es) | Inhibidores del factor d del complemento para administración oral | |
| JP2019526634A5 (enExample) | ||
| JP2018515463A5 (enExample) | ||
| FR2903107B1 (fr) | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique | |
| JP2014523413A5 (enExample) |